

ACURA PHARMACEUTICALS, INC  
Form 8-K  
May 27, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934**

May 27, 2008  
Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in Charter)

---

**State of New York**  
(State of Other Jurisdiction  
of Incorporation)

**1-10113**  
(Commission File Number)

**11-0853640**  
(I.R.S. Employer  
Identification Number)

**616 N. North Court, Suite 120**  
**Palatine, Illinois 60067**  
(Address of principal executive offices) (Zip Code)

**(847) 705-7709**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))



**Item 8.01**

**Other Events**

On May 23, 2008, King Pharmaceuticals Research and Development, Inc. (“King”), a wholly-owned subsidiary of King Pharmaceuticals, Inc., exercised an option under the License, Development and Commercialization Agreement dated as of October 30, 2007 between King and us, to license from us a third immediate-release opioid analgesic product utilizing our proprietary AVERSION® Technology and paid us the \$3 million exercise price. A press release issued by us in connection with the option exercise is furnished as Exhibit 99.1.

**Item 9.01**

**Financial Statements and Exhibits**

**Exhibit Number**

**Description**

99.1

Press Release of the Registrant dated May 27, 2008.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter Clemens

---

Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: May 27, 2008

---

**EXHIBIT INDEX**

**ExhibitNumber**

**Description**

99.1

Press Release of the Registrant dated May 27, 2008.

---